ondansetron has been researched along with Acute Disease in 68 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with AG who have failed ORT." | 9.15 | Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial. ( Arrighini, A; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Di Pietro, P; Guala, A; Maestro, A; Mannelli, F; Marchetti, F; Messi, G; Pazzaglia, A; Perri, F; Reale, A; Renna, S; Ronfani, L; Rovere, F; Tondelli, MT; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2011) |
| "In subjects with acute gastritis/acute gastroenteritis and mild to moderate dehydration who failed initial oral rehydration therapy, the proportion of children who received intravenous hydration was smaller in the ondansetron group than in the placebo group." | 9.13 | The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. ( Hepps, TS; McQuillen, KK; Roslund, G, 2008) |
| "Intravenous ondansetron decreases vomiting in children with gastroenteritis." | 9.10 | Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. ( Fleisher, GR; Reeves, JJ; Shannon, MW, 2002) |
| "Ondansetron was effective in reducing the emesis from gastroenteritis during the ED phase of oral rehydration and in lowering the rates of intravenous fluid administration and hospital admission." | 9.10 | A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. ( Kozinetz, CA; Moro-Sutherland, D; Ramsook, C; Sahagun-Carreon, I, 2002) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 9.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| "048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0." | 9.08 | Antiemetic activity of ondansetron in acute gastroenteritis. ( Cubeddu, LX; Gonzalez, V; Guariguata, J; Miller, IA; Paska, W; Seijas, J; Talmaciu, I; Trujillo, LM, 1997) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 9.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "The aim of the study was to compare granisetron (GRA) with ondansetron (OND) in the prevention of acute emesis in consecutive chemotherapy-naive patients admitted to our department to receive a cytotoxic treatment containing cisplatinum (CP) at a dose > or = 50 mg/m2." | 9.08 | An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. ( Angelelli, B; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E, 1996) |
| "To determine the contribution of dexamethasone to the efficacy of the 5-hydroxytryptamine antagonist ondansetron in control of cisplatin induced nausea and vomiting." | 9.07 | Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? ( Allan, SG; Bruntsch, U; Coleman, RE; Cornbleet, MA; Gallmeier, WM; Leonard, RC; Nicolson, M; Smyth, JF; Upadhyaya, BK, 1991) |
| "A multicentre, randomised, double-blind, cross-over trial was done to compare the efficacy and safety of a serotonin receptor antagonist--ondansetron--and dexamethasone in the prophylaxis of acute and delayed emesis and nausea induced by moderately emetogenic non-platinum-containing chemotherapy regimens." | 9.07 | Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. ( Carney, DN; Cassidy, J; Cunningham, D; Hill, AS; Hutcheon, AW; Jones, AL; Kaye, SB; Sikora, K; Soukop, M, 1991) |
| "Forty-seven patients receiving non-cisplatin-containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron plus dexamethasone and tropisetron plus dexamethasone in the prophylaxis of acute vomiting was evaluated." | 9.07 | Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. ( Jantunen, IT; Johansson, RT; Kataja, VV, 1992) |
| "These data suggest that although both ondansetron and granisetron are very effective drugs for the control of acute emesis, their efficacy against delayed emesis is still not entirely satisfactory." | 9.07 | Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. ( Cannata, G; Cipolla, C; Curto, G; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A; Valenza, R, 1994) |
| "The antiemetic efficacy of ondansetron and dexamethasone (Ondex) was randomly compared to that of high-dose metoclopramide, dexamethasone, and orphenadrine (Control) in the prevention of emesis induced by cyclophosphamide-doxorubicin chemotherapy in 64 chemotherapy-naive breast cancer patients." | 9.07 | Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses ( Campora, E; Giudici, S; Merlini, L; Rosso, R; Rubagotti, A, 1994) |
| "Sixty five chemotherapy naive patients receiving cisplatin (50-120 mg/m2) containing chemotherapy participated in an evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and emesis." | 9.06 | Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis. ( Bella, M; Bracarda, S; Cetto, G; Del Favero, A; Donati, D; Marangolo, M; Roila, F; Tonato, M, 1990) |
| "This review aimed to meta-analyze evidence of efficacy and safety of one single dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis." | 9.05 | Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis. ( Biagi, C; Filice, E; Fugetto, F; Gori, D; Lanari, M; Pierantoni, L, 2020) |
| " ondansetron is an effective antiemetic in children with gastroenteritis, but data from low- and middle-income countries are sparse." | 9.05 | Effect of ondansetron on vomiting associated with acute gastroenteritis in a developing country: a meta-analysis. ( Wu, HL; Zhan, X, 2020) |
| " Treatment with ondansetron compared with placebo increased the chance for vomiting cessation up to 1 h after drug administration, relative risk, RR, 1." | 8.93 | Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. ( Kołodziej, M; Szajewska, H; Tomasik, E; Ziółkowska, E, 2016) |
| "Despite the advance in supportive care that occurred with the introduction of selective serotonin subtype 3 (5-HT3) receptor antagonists, control of chemotherapy-induced nausea and vomiting (CINV) with first-generation agents (ondansetron, dolasetron, and granisetron) is less than ideal." | 8.82 | Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. ( Rubenstein, EB, 2004) |
| " Early clinical studies therefore examined ondansetron treatment to establish an optimal dosing schedule for acute emesis." | 8.77 | Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. ( Marty, M, 1989) |
| "Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge." | 8.12 | Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis. ( Bhatt, SR; Casper, TC; Farion, KJ; Freedman, SB; Gouin, S; Hurley, K; Levine, AC; Mahajan, P; O'Connell, KJ; Olsen, CS; Poonai, N; Powell, EC; Rogers, AJ; Roskind, CG; Sapien, RE; Schnadower, D; Schuh, S; Tarr, PI; Vance, C, 2022) |
| "This study describes the introduction of Ondansetron to an established waiting room Oral Rehydration Therapy (ORT) for Emergency Department (ED) children with acute gastroenteritis, and evaluates its impact on intravenous fluid administration and admissions." | 7.79 | The addition of ondansetron to a oral rehydration protocol for children with acute gastroenteritis. ( Crowley, E; Martin, C; Mullarkey, C, 2013) |
| " Ondansetron has been well tolerated when used to control nausea and vomiting in patients receiving chemotherapy." | 7.73 | Ondansetron for acute gastroenteritis in children. ( Goldman, RD; Mehta, S, 2006) |
| "Domperidone was not effective for the symptomatic treatment of vomiting during acute gastroenteritis." | 6.82 | Oral Ondansetron versus Domperidone for Acute Gastroenteritis in Pediatric Emergency Departments: Multicenter Double Blind Randomized Controlled Trial. ( Arrighini, A; Barbi, E; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Guala, A; Maestro, A; Marchetti, F; Mazzoni, E; Pazzaglia, A; Perri, PF; Reale, A; Renna, S; Ronfani, L; Rovere, F; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2016) |
| "Ondansetron use has increased significantly; however, 'real-world' studies of effectiveness have documented less impressive clinical impacts." | 6.52 | Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries. ( Finkelstein, Y; Freedman, SB; Schnadower, D, 2015) |
| "Ondansetron was administered as follows: 8 mg intravenously before the start of chemotherapy, followed by 8 mg orally three times daily for 10 days." | 5.29 | Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia. ( Braken, JB; de Pauw, BE; Koopmans, PP; Raemaekers, JM, 1993) |
| "To compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with AG who have failed ORT." | 5.15 | Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial. ( Arrighini, A; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Di Pietro, P; Guala, A; Maestro, A; Mannelli, F; Marchetti, F; Messi, G; Pazzaglia, A; Perri, F; Reale, A; Renna, S; Ronfani, L; Rovere, F; Tondelli, MT; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2011) |
| "Palonosetron and ondansetron are two selective 5-hydroxytryptamine (5-HT3) receptor antagonists that have shown remarkable efficacy in controlling nausea and vomiting following administration of moderately emetic anticancer chemotherapy." | 5.14 | Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. ( Atri, R; Bhutani, G; Dhankar, R; Gupta, MC; Kaushal, J; Kaushal, V; Verma, S, 2010) |
| "In subjects with acute gastritis/acute gastroenteritis and mild to moderate dehydration who failed initial oral rehydration therapy, the proportion of children who received intravenous hydration was smaller in the ondansetron group than in the placebo group." | 5.13 | The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. ( Hepps, TS; McQuillen, KK; Roslund, G, 2008) |
| "A single intravenous dose of 8 mg of ondansetron and 20 mg of dexamethasone had good control of acute nausea and vomiting only in those who received non-cisplatin containing regimens and those older than 45 years." | 5.12 | Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. ( Manusirivithaya, S; Pradermdee, P; Sukwattana, P; Tangjitgamol, S; Thavaramara, T, 2006) |
| "Intravenous ondansetron decreases vomiting in children with gastroenteritis." | 5.10 | Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. ( Fleisher, GR; Reeves, JJ; Shannon, MW, 2002) |
| "Ondansetron was effective in reducing the emesis from gastroenteritis during the ED phase of oral rehydration and in lowering the rates of intravenous fluid administration and hospital admission." | 5.10 | A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. ( Kozinetz, CA; Moro-Sutherland, D; Ramsook, C; Sahagun-Carreon, I, 2002) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 5.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| "The aim of the study was to compare granisetron (GRA) with ondansetron (OND) in the prevention of acute emesis in consecutive chemotherapy-naive patients admitted to our department to receive a cytotoxic treatment containing cisplatinum (CP) at a dose > or = 50 mg/m2." | 5.08 | An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. ( Angelelli, B; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E, 1996) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 5.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0." | 5.08 | Antiemetic activity of ondansetron in acute gastroenteritis. ( Cubeddu, LX; Gonzalez, V; Guariguata, J; Miller, IA; Paska, W; Seijas, J; Talmaciu, I; Trujillo, LM, 1997) |
| "To determine the contribution of dexamethasone to the efficacy of the 5-hydroxytryptamine antagonist ondansetron in control of cisplatin induced nausea and vomiting." | 5.07 | Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? ( Allan, SG; Bruntsch, U; Coleman, RE; Cornbleet, MA; Gallmeier, WM; Leonard, RC; Nicolson, M; Smyth, JF; Upadhyaya, BK, 1991) |
| "Forty-seven patients receiving non-cisplatin-containing chemotherapy were entered in a prospective study in which the efficacy of ondansetron plus dexamethasone and tropisetron plus dexamethasone in the prophylaxis of acute vomiting was evaluated." | 5.07 | Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. ( Jantunen, IT; Johansson, RT; Kataja, VV, 1992) |
| "The antiemetic efficacy of ondansetron and dexamethasone (Ondex) was randomly compared to that of high-dose metoclopramide, dexamethasone, and orphenadrine (Control) in the prevention of emesis induced by cyclophosphamide-doxorubicin chemotherapy in 64 chemotherapy-naive breast cancer patients." | 5.07 | Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses ( Campora, E; Giudici, S; Merlini, L; Rosso, R; Rubagotti, A, 1994) |
| " dexamethasone and oral metoclopramide) for delayed emesis, while they had received either i." | 5.07 | Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research. ( , 1994) |
| "These data suggest that although both ondansetron and granisetron are very effective drugs for the control of acute emesis, their efficacy against delayed emesis is still not entirely satisfactory." | 5.07 | Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. ( Cannata, G; Cipolla, C; Curto, G; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A; Valenza, R, 1994) |
| "Ondansetron plus dexamethasone was significantly more efficacious and better tolerated than metoclopramide plus dexamethasone and diphenhydramine during three cycles of chemotherapy and, in contrast to the metoclopramide regimen, the efficacy of ondansetron plus dexamethasone, at least for vomiting, is maintained in subsequent cycles." | 5.07 | Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research. ( , 1993) |
| "A multicentre, randomised, double-blind, cross-over trial was done to compare the efficacy and safety of a serotonin receptor antagonist--ondansetron--and dexamethasone in the prophylaxis of acute and delayed emesis and nausea induced by moderately emetogenic non-platinum-containing chemotherapy regimens." | 5.07 | Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. ( Carney, DN; Cassidy, J; Cunningham, D; Hill, AS; Hutcheon, AW; Jones, AL; Kaye, SB; Sikora, K; Soukop, M, 1991) |
| "Sixty five chemotherapy naive patients receiving cisplatin (50-120 mg/m2) containing chemotherapy participated in an evaluation of ondansetron, a 5-HT3 receptor antagonist, in the prophylaxis of acute and delayed nausea and emesis." | 5.06 | Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis. ( Bella, M; Bracarda, S; Cetto, G; Del Favero, A; Donati, D; Marangolo, M; Roila, F; Tonato, M, 1990) |
| "This review aimed to meta-analyze evidence of efficacy and safety of one single dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis." | 5.05 | Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis. ( Biagi, C; Filice, E; Fugetto, F; Gori, D; Lanari, M; Pierantoni, L, 2020) |
| "Ondansetron is the only intervention that revealed an effect on the cessation of vomiting, on preventing hospitalizations, and in reducing the need for intravenous rehydration." | 5.05 | Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis. ( Acosta-Reyes, J; Florez, ID; Niño-Serna, LF; Veroniki, AA, 2020) |
| " ondansetron is an effective antiemetic in children with gastroenteritis, but data from low- and middle-income countries are sparse." | 5.05 | Effect of ondansetron on vomiting associated with acute gastroenteritis in a developing country: a meta-analysis. ( Wu, HL; Zhan, X, 2020) |
| "Well-designed investigations suggest that antagonists of the type 3 serotonin receptor, most frequently oral ondansetron, reduce the rate of vomiting, improve the tolerance of oral rehydration, and reduce the need for intravenous rehydration." | 4.98 | Clinical Practice: Nausea and vomiting in acute gastroenteritis: physiopathology and management. ( Agostoni, C; Bianchetti, MG; Canziani, BC; Fossali, EF; Lava, SAG; Milani, GP; Uestuener, P, 2018) |
| " Treatment with ondansetron compared with placebo increased the chance for vomiting cessation up to 1 h after drug administration, relative risk, RR, 1." | 4.93 | Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. ( Kołodziej, M; Szajewska, H; Tomasik, E; Ziółkowska, E, 2016) |
| "Oral ondansetron increased the proportion of patients who had ceased vomiting and reduced the number needing intravenous rehydration and immediate hospital admission." | 4.87 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Carter, B; Fedorowicz, Z; Jagannath, VA, 2011) |
| "The small number of included trials provided some limited evidence favouring the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.85 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Al-Hashimi, H; Alhashimi, D; Fedorowicz, Z, 2009) |
| "The small number of included trials provided some, albeit weak and unreliable, evidence which appeared to favor the use of ondansetron and metoclopramide over placebo to reduce the number of episodes of vomiting due to gastroenteritis in children." | 4.83 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Alhashimi, D; Alhashimi, H; Fedorowicz, Z, 2006) |
| " Although no data were available for the precise time to cessation of vomiting (the primary outcome specified in the protocol for this review), one trial reported that the proportion of patients without vomiting over a 24 hour period was higher in the ondansetron and metoclopramide groups than placebo." | 4.83 | Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. ( Alhashimi, D; Alhashimi, H; Fedorowicz, Z, 2006) |
| "Despite the advance in supportive care that occurred with the introduction of selective serotonin subtype 3 (5-HT3) receptor antagonists, control of chemotherapy-induced nausea and vomiting (CINV) with first-generation agents (ondansetron, dolasetron, and granisetron) is less than ideal." | 4.82 | Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. ( Rubenstein, EB, 2004) |
| " Early clinical studies therefore examined ondansetron treatment to establish an optimal dosing schedule for acute emesis." | 4.77 | Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. ( Marty, M, 1989) |
| "Among preschool-aged children with gastroenteritis seeking ED care, oral ondansetron administration was associated with a reduction in index ED visit intravenous fluid administration; it was not associated with intravenous fluids administered within 72 hours, hospitalization, or vomiting and diarrhea in the 24 hours following discharge." | 4.12 | Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis. ( Bhatt, SR; Casper, TC; Farion, KJ; Freedman, SB; Gouin, S; Hurley, K; Levine, AC; Mahajan, P; O'Connell, KJ; Olsen, CS; Poonai, N; Powell, EC; Rogers, AJ; Roskind, CG; Sapien, RE; Schnadower, D; Schuh, S; Tarr, PI; Vance, C, 2022) |
| "This study describes the introduction of Ondansetron to an established waiting room Oral Rehydration Therapy (ORT) for Emergency Department (ED) children with acute gastroenteritis, and evaluates its impact on intravenous fluid administration and admissions." | 3.79 | The addition of ondansetron to a oral rehydration protocol for children with acute gastroenteritis. ( Crowley, E; Martin, C; Mullarkey, C, 2013) |
| " Dolasetron ( n=157), granisetron ( n=81), and ondansetron ( n=131) achieved complete control of vomiting in 89." | 3.74 | Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? ( Awan, FT; Chaudhary, L; Hamadani, M; Khan, JK; Kojouri, K; Ozer, H; Tfayli, A, 2007) |
| " Ondansetron has been well tolerated when used to control nausea and vomiting in patients receiving chemotherapy." | 3.73 | Ondansetron for acute gastroenteritis in children. ( Goldman, RD; Mehta, S, 2006) |
| " Intravenous ondansetron 8 mg and dexamethasone 20 mg served as an alternative regimen in patients <30 years old with a history of extrapyramidal manifestations or emesis in previous cycles." | 3.70 | Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy. ( Catalán Arlandis, JL; Jiménez Torres, NV, 2000) |
| "The primary outcome was the incidence of postoperative nausea and vomiting (PONV) during the first postoperative day." | 2.84 | Randomized clinical trial of preoperative dexamethasone on postoperative nausea and vomiting after laparoscopy for suspected appendicitis. ( Gögenur, I; Kirkegaard, A; Kleif, J; Vilandt, J, 2017) |
| "Domperidone was not effective for the symptomatic treatment of vomiting during acute gastroenteritis." | 2.82 | Oral Ondansetron versus Domperidone for Acute Gastroenteritis in Pediatric Emergency Departments: Multicenter Double Blind Randomized Controlled Trial. ( Arrighini, A; Barbi, E; Bertolani, P; Biban, P; Bonati, M; Clavenna, A; Da Dalt, L; Guala, A; Maestro, A; Marchetti, F; Mazzoni, E; Pazzaglia, A; Perri, PF; Reale, A; Renna, S; Ronfani, L; Rovere, F; Urbino, AF; Valletta, E; Vitale, A; Zangardi, T; Zanon, D, 2016) |
| " Measures to more effectively prevent nephrotoxicity should be developed for the safe use of heptaplatin." | 2.70 | Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002) |
| "mL(-1)." | 2.70 | Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. ( Arcioni, R; della Rocca, M; Gasparetto, A; Pietropaoli, P; Romano, R; Romanò, S, 2002) |
| "Ondansetron was effective as a primary pain reliever in 14 (42." | 2.70 | Ondansetron versus diclofenac sodium in the treatment of acute ureteral colic: a double blind controlled trial. ( Canda, E; Coşkun, F; Ergene, U; Fowler, J; Kirkali, Z; Pekdemir, M, 2001) |
| "Ondansetron use has increased significantly; however, 'real-world' studies of effectiveness have documented less impressive clinical impacts." | 2.52 | Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries. ( Finkelstein, Y; Freedman, SB; Schnadower, D, 2015) |
| " Although probiotics appear to be an effective option for the treatment of AGE amongst hospitalized children, outpatient data is lacking and more studies are urgently needed to determine the optimal organism, dosing and duration of treatment." | 2.49 | Treatment of acute gastroenteritis in children: an overview of systematic reviews of interventions commonly used in developed countries. ( Ali, S; Freedman, SB; Gouin, S; Hartling, L; Oleszczuk, M, 2013) |
| "Much of the research on migraine treatment regimens involves antidopaminergic antiemetics such as prochlorperazine and metoclopramide." | 1.56 | Ondansetron for Acute Migraine in the Pediatric Emergency Department. ( Heilbrunn, B; Talai, A, 2020) |
| "Ondansetron has proven to be a safe and effective adjunct in children with vomiting." | 1.46 | Clinical Pathway Produces Sustained Improvement in Acute Gastroenteritis Care. ( Brown, JC; Klein, EJ; Rutman, L, 2017) |
| "For moderate dehydration, eight CPGs advocated nasogastric (NG) rehydration in preference to intravenous (IV) rehydration." | 1.35 | Emergency department management of gastro-enteritis in Australia and New Zealand. ( Babl, FE; Borland, M; Schutz, J; Sheriff, N, 2008) |
| "The ondansetron treated rats showed only a non-significant decrease in break point." | 1.31 | Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. ( Davidson, C; Ellinwood, EH; Lee, TH; Xiong, Z, 2002) |
| "Pretreatment with clonidine, prazosin or ondansetron did not modify the raised ICP-induced inhibition of gastric emptying." | 1.30 | Acute intracranial hypertension-induced inhibition of gastric emptying: evaluation in conscious rats. ( Gupta, YK; Kacker, V; Mehta, VS, 1999) |
| "Ondansetron was administered as follows: 8 mg intravenously before the start of chemotherapy, followed by 8 mg orally three times daily for 10 days." | 1.29 | Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia. ( Braken, JB; de Pauw, BE; Koopmans, PP; Raemaekers, JM, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.94) | 18.7374 |
| 1990's | 19 (27.94) | 18.2507 |
| 2000's | 23 (33.82) | 29.6817 |
| 2010's | 17 (25.00) | 24.3611 |
| 2020's | 7 (10.29) | 2.80 |
| Authors | Studies |
|---|---|
| Gill, PJ | 1 |
| Thomas, E | 1 |
| Van den Bruel, A | 1 |
| Niño-Serna, LF | 1 |
| Acosta-Reyes, J | 1 |
| Veroniki, AA | 1 |
| Florez, ID | 1 |
| Fugetto, F | 1 |
| Filice, E | 1 |
| Biagi, C | 1 |
| Pierantoni, L | 1 |
| Gori, D | 1 |
| Lanari, M | 1 |
| Talai, A | 1 |
| Heilbrunn, B | 1 |
| Wu, HL | 1 |
| Zhan, X | 1 |
| Funk, A | 1 |
| Schnadower, D | 3 |
| Freedman, SB | 4 |
| Powell, EC | 1 |
| Roskind, CG | 1 |
| Olsen, CS | 1 |
| Casper, TC | 1 |
| Tarr, PI | 1 |
| O'Connell, KJ | 1 |
| Levine, AC | 1 |
| Poonai, N | 1 |
| Schuh, S | 1 |
| Rogers, AJ | 1 |
| Bhatt, SR | 1 |
| Gouin, S | 2 |
| Mahajan, P | 1 |
| Vance, C | 1 |
| Hurley, K | 1 |
| Farion, KJ | 1 |
| Sapien, RE | 1 |
| Rutman, L | 1 |
| Klein, EJ | 1 |
| Brown, JC | 1 |
| Canziani, BC | 1 |
| Uestuener, P | 1 |
| Fossali, EF | 1 |
| Lava, SAG | 1 |
| Bianchetti, MG | 1 |
| Agostoni, C | 1 |
| Milani, GP | 1 |
| Bergemalm, J | 1 |
| Ludvigsson, JF | 1 |
| Ali, S | 1 |
| Oleszczuk, M | 1 |
| Hartling, L | 1 |
| Mullarkey, C | 1 |
| Crowley, E | 1 |
| Martin, C | 1 |
| Finkelstein, Y | 1 |
| Tomasik, E | 1 |
| Ziółkowska, E | 1 |
| Kołodziej, M | 1 |
| Szajewska, H | 1 |
| Marzuillo, P | 1 |
| Vecchione, E | 1 |
| D'Anna, C | 1 |
| Tipo, V | 1 |
| Marchetti, F | 2 |
| Bonati, M | 2 |
| Maestro, A | 2 |
| Zanon, D | 2 |
| Rovere, F | 2 |
| Arrighini, A | 2 |
| Barbi, E | 1 |
| Bertolani, P | 2 |
| Biban, P | 2 |
| Da Dalt, L | 2 |
| Guala, A | 2 |
| Mazzoni, E | 1 |
| Pazzaglia, A | 2 |
| Perri, PF | 1 |
| Reale, A | 2 |
| Renna, S | 2 |
| Urbino, AF | 2 |
| Valletta, E | 2 |
| Vitale, A | 2 |
| Zangardi, T | 2 |
| Clavenna, A | 2 |
| Ronfani, L | 2 |
| Kleif, J | 1 |
| Kirkegaard, A | 1 |
| Vilandt, J | 1 |
| Gögenur, I | 1 |
| Schutz, J | 1 |
| Babl, FE | 1 |
| Sheriff, N | 1 |
| Borland, M | 1 |
| Simonetto, M | 1 |
| Ferigo, L | 1 |
| Zanet, L | 1 |
| Capus, L | 1 |
| Antonutti, L | 1 |
| Zorzon, M | 1 |
| Pizzolato, G | 1 |
| Alhashimi, D | 3 |
| Al-Hashimi, H | 1 |
| Fedorowicz, Z | 4 |
| Trepanier, L | 1 |
| Beer, GM | 1 |
| Goldscheider, E | 1 |
| Weber, A | 1 |
| Lehmann, K | 1 |
| Sánchez Etxaniz, J | 1 |
| Paniagua Calzón, N | 1 |
| Gómez Cortés, B | 1 |
| Kaushal, J | 1 |
| Gupta, MC | 1 |
| Kaushal, V | 1 |
| Bhutani, G | 1 |
| Dhankar, R | 1 |
| Atri, R | 1 |
| Verma, S | 1 |
| Di Pietro, P | 1 |
| Mannelli, F | 1 |
| Messi, G | 1 |
| Perri, F | 1 |
| Tondelli, MT | 1 |
| Jagannath, VA | 1 |
| Carter, B | 1 |
| Cayley, WE | 1 |
| Ahn, JH | 1 |
| Kang, YK | 1 |
| Kim, TW | 1 |
| Bahng, H | 1 |
| Chang, HM | 1 |
| Kang, WC | 1 |
| Kim, WK | 1 |
| Lee, JS | 1 |
| Park, JS | 1 |
| Davidson, C | 1 |
| Lee, TH | 1 |
| Xiong, Z | 1 |
| Ellinwood, EH | 1 |
| Spirko, BA | 1 |
| Rubenstein, EB | 1 |
| Alhashimi, H | 2 |
| Mehta, S | 1 |
| Goldman, RD | 1 |
| Freedman, S | 1 |
| Adler, M | 1 |
| Seshadri, R | 1 |
| Powell, E | 1 |
| Pradermdee, P | 1 |
| Manusirivithaya, S | 1 |
| Tangjitgamol, S | 1 |
| Thavaramara, T | 1 |
| Sukwattana, P | 1 |
| Hamadani, M | 1 |
| Chaudhary, L | 1 |
| Awan, FT | 1 |
| Khan, JK | 1 |
| Kojouri, K | 1 |
| Ozer, H | 1 |
| Tfayli, A | 1 |
| Roslund, G | 1 |
| Hepps, TS | 1 |
| McQuillen, KK | 1 |
| Rice, GP | 1 |
| Ebers, GC | 1 |
| Campora, E | 1 |
| Giudici, S | 1 |
| Merlini, L | 1 |
| Rubagotti, A | 1 |
| Rosso, R | 1 |
| Chevallier, B | 1 |
| Marty, M | 2 |
| Paillarse, JM | 1 |
| Gebbia, V | 1 |
| Cannata, G | 1 |
| Testa, A | 1 |
| Curto, G | 1 |
| Valenza, R | 1 |
| Cipolla, C | 1 |
| Latteri, MA | 1 |
| Gebbia, N | 1 |
| Braken, JB | 1 |
| Raemaekers, JM | 1 |
| Koopmans, PP | 1 |
| de Pauw, BE | 1 |
| Martoni, A | 1 |
| Angelelli, B | 1 |
| Guaraldi, M | 1 |
| Strocchi, E | 1 |
| Pannuti, F | 1 |
| Bosnjak, SM | 2 |
| Neskovic-Konstantinovic, ZB | 2 |
| Jovanovic-Micic, DJ | 1 |
| Mitrovic, LB | 1 |
| Radulovic, SS | 2 |
| Tremont-Lukats, IW | 1 |
| Teixeira, GM | 1 |
| Cubeddu, LX | 1 |
| Trujillo, LM | 1 |
| Talmaciu, I | 1 |
| Gonzalez, V | 1 |
| Guariguata, J | 1 |
| Seijas, J | 1 |
| Miller, IA | 1 |
| Paska, W | 1 |
| Granados, LM | 1 |
| Ballester, F | 1 |
| Suárez, F | 1 |
| Sánchez-Peña, J | 1 |
| Navas, E | 1 |
| Khoo, VS | 1 |
| Rainford, K | 1 |
| Horwich, A | 1 |
| Dearnaley, DP | 1 |
| Kacker, V | 1 |
| Mehta, VS | 1 |
| Gupta, YK | 1 |
| Bosek, V | 1 |
| Hu, P | 1 |
| Robinson, LA | 1 |
| Forni, C | 1 |
| Ferrari, S | 1 |
| Loro, L | 1 |
| Mazzei, T | 1 |
| Beghelli, C | 1 |
| Biolchini, A | 1 |
| Simoni, P | 1 |
| Tremosini, M | 1 |
| Strazzari, S | 1 |
| Puggioli, C | 1 |
| Bacci, G | 1 |
| Catalán Arlandis, JL | 1 |
| Jiménez Torres, NV | 1 |
| Liaw, CC | 1 |
| Wang, CH | 1 |
| Chang, HK | 1 |
| Kao, CY | 1 |
| Huang, JS | 1 |
| Susnjar, S | 1 |
| Mitrovi, LB | 1 |
| Ramsook, C | 1 |
| Sahagun-Carreon, I | 1 |
| Kozinetz, CA | 1 |
| Moro-Sutherland, D | 1 |
| Reeves, JJ | 1 |
| Shannon, MW | 1 |
| Fleisher, GR | 1 |
| Arcioni, R | 1 |
| della Rocca, M | 1 |
| Romanò, S | 1 |
| Romano, R | 1 |
| Pietropaoli, P | 1 |
| Gasparetto, A | 1 |
| Ergene, U | 1 |
| Pekdemir, M | 1 |
| Canda, E | 1 |
| Kirkali, Z | 1 |
| Fowler, J | 1 |
| Coşkun, F | 1 |
| Kaye, SB | 2 |
| Khayat, D | 1 |
| Aapro, M | 1 |
| Diehl, V | 1 |
| Jantunen, IT | 1 |
| Kataja, VV | 1 |
| Johansson, RT | 1 |
| Jones, AL | 1 |
| Hill, AS | 1 |
| Soukop, M | 1 |
| Hutcheon, AW | 1 |
| Cassidy, J | 1 |
| Sikora, K | 1 |
| Carney, DN | 1 |
| Cunningham, D | 1 |
| Smyth, JF | 1 |
| Coleman, RE | 1 |
| Nicolson, M | 1 |
| Gallmeier, WM | 1 |
| Leonard, RC | 1 |
| Cornbleet, MA | 1 |
| Allan, SG | 1 |
| Upadhyaya, BK | 1 |
| Bruntsch, U | 1 |
| Roila, F | 1 |
| Bracarda, S | 1 |
| Tonato, M | 1 |
| Marangolo, M | 1 |
| Bella, M | 1 |
| Donati, D | 1 |
| Cetto, G | 1 |
| Del Favero, A | 1 |
| Hesketh, PJ | 1 |
| Murphy, WK | 1 |
| Lester, EP | 1 |
| Gandara, DR | 1 |
| Khojasteh, A | 1 |
| Tapazoglou, E | 1 |
| Sartiano, GP | 1 |
| White, DR | 1 |
| Werner, K | 1 |
| Chubb, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of Pleuran in Treatment of Acute Gastroenteritis in Children- a Randomized, Placebo-controlled, Double-blind Trial[NCT03988257] | Phase 4 | 27 participants (Actual) | Interventional | 2019-06-24 | Completed | ||
| Dexamethasone Preoperative for Patients Undergoing Laparoscopy for Suspected Appendicitis[NCT02415335] | Phase 2 | 119 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Oral Ondansetron vs Domperidone for Symptomatic Treatment of Vomiting During Acute Gastroenteritis in Children: Multicentre Randomized Controlled Trial[NCT01257672] | Phase 3 | 356 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Comparison of Efficacy of Ondansetron Versus Metoclopramide for Vomiting in Children With Acute Gastroenteritis: Randomized Controlled Clinical Trial[NCT02619201] | Phase 3 | 250 participants (Anticipated) | Interventional | 2015-11-30 | Not yet recruiting | ||
| Ondansetron vs. Placebo in the Management of Children With Dehydration Due to Acute Gastroenteritis[NCT00691275] | 0 participants (Actual) | Interventional | 2008-09-30 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for ondansetron and Acute Disease
| Article | Year |
|---|---|
Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis.
Topics: Acute Disease; Antiemetics; Child; Child, Preschool; Dexamethasone; Diarrhea; Dimenhydrinate; Domper | 2020 |
Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Drug Administration Schedule; Gastroenteritis; Humans | 2020 |
Effect of ondansetron on vomiting associated with acute gastroenteritis in a developing country: a meta-analysis.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Dehydration; Developing Countries; | 2020 |
Update on nonantibiotic therapies for acute gastroenteritis.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Anti-Bacterial | 2020 |
Clinical Practice: Nausea and vomiting in acute gastroenteritis: physiopathology and management.
Topics: Acute Disease; Antiemetics; Combined Modality Therapy; Fluid Therapy; Gastroenteritis; Humans; Nause | 2018 |
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Fluid Therapy; Gastroenteritis; Hos | 2018 |
Treatment of acute gastroenteritis in children: an overview of systematic reviews of interventions commonly used in developed countries.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adolescent; Antiemetics; Child; Ch | 2013 |
Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries.
Topics: Acute Disease; Antiemetics; Child; Combined Modality Therapy; Developed Countries; Gastroenteritis; | 2015 |
Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Antiemetics; Child; Child, Prescho | 2016 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Gastroenteritis; Humans; Metoclopra | 2009 |
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indol | 2010 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Fluid Therapy; Gastroenteritis; Hos | 2011 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome | 2004 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Gastroenteritis; Humans; Metoclopramide; Ondansetron; | 2006 |
Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Gastroenteritis; Humans; Metoclopramide; Ondansetron; | 2006 |
Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Imidazoles; Male; Middle Aged; N | 1989 |
28 trials available for ondansetron and Acute Disease
| Article | Year |
|---|---|
Oral Ondansetron versus Domperidone for Acute Gastroenteritis in Pediatric Emergency Departments: Multicenter Double Blind Randomized Controlled Trial.
Topics: Acute Disease; Administration, Oral; Antiemetics; Child; Child, Preschool; Domperidone; Double-Blind | 2016 |
Randomized clinical trial of preoperative dexamethasone on postoperative nausea and vomiting after laparoscopy for suspected appendicitis.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Appendectomy; Appendicitis; Dexamethasone; | 2017 |
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Th | 2010 |
Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial.
Topics: Acute Disease; Administration, Oral; Antiemetics; Child; Child, Preschool; Clinical Protocols; Dompe | 2011 |
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2002 |
Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Topics: Acute Disease; Adult; Age Factors; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents; Cis | 2006 |
The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial.
Topics: Acute Disease; Administration, Oral; Antiemetics; Chi-Square Distribution; Child; Child, Preschool; | 2008 |
Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 1994 |
Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group.
Topics: Acute Disease; Adult; Antiemetics; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Female | 1994 |
Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
Topics: Acute Disease; Chi-Square Distribution; Cisplatin; Dexamethasone; Diphenhydramine; Drug Therapy, Com | 1994 |
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; | 1994 |
Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dexamethasone; Diphenhydramin | 1993 |
An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Femal | 1996 |
Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial.
Topics: Acute Disease; Antiemetics; Antineoplastic Agents; Cisplatin; Data Interpretation, Statistical; Gran | 1996 |
Antiemetic activity of ondansetron in acute gastroenteritis.
Topics: Acute Disease; Antiemetics; Child; Child, Preschool; Diarrhea; Female; Fluid Therapy; Gastroenteriti | 1997 |
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study.
Topics: Acute Disease; Adult; Antiemetics; Diarrhea; Gastrointestinal Diseases; Humans; Lymphatic Metastasis | 1997 |
Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone | 2000 |
High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemoth | 2000 |
A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis.
Topics: Acute Disease; Administration, Oral; Child; Child, Preschool; Diarrhea; Double-Blind Method; Female; | 2002 |
Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; | 2002 |
Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans.
Topics: Acute Disease; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Antiemetics; Drug Interactio | 2002 |
Ondansetron versus diclofenac sodium in the treatment of acute ureteral colic: a double blind controlled trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colic; Diclo | 2001 |
Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; | 1992 |
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Dexamethasone; Doubl | 1991 |
Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
Topics: Acute Disease; Adolescent; Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; | 1991 |
Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis.
Topics: Acute Disease; Adult; Aged; Antiemetics; Cisplatin; Drug Administration Schedule; Drug Evaluation; F | 1990 |
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Human | 1989 |
24 other studies available for ondansetron and Acute Disease
| Article | Year |
|---|---|
Managing paediatric gastroenteritis in primary care: is there a role for ondansetron?
Topics: Acute Disease; Child; Gastroenteritis; Humans; Ondansetron; Primary Health Care; Vomiting | 2021 |
Ondansetron for Acute Migraine in the Pediatric Emergency Department.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Dopamine Antagonists; Emergency Service, Hospital; Fe | 2020 |
Oral Ondansetron Administration in Children Seeking Emergency Department Care for Acute Gastroenteritis: A Patient-Level Propensity-Matched Analysis.
Topics: Acute Disease; Administration, Oral; Antiemetics; Child, Preschool; Diarrhea; Emergency Service, Hos | 2022 |
Clinical Pathway Produces Sustained Improvement in Acute Gastroenteritis Care.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Child, Preschool; Combined Modality Therapy; Critical | 2017 |
The addition of ondansetron to a oral rehydration protocol for children with acute gastroenteritis.
Topics: Acute Disease; Antiemetics; Child, Preschool; Emergency Service, Hospital; Female; Fluid Therapy; Ga | 2013 |
Ondansetron as the first approach in the management of the patients with acute gastroenteritis visiting the pediatric emergency department: A single-center experience.
Topics: Acute Disease; Antiemetics; Child, Preschool; Emergency Service, Hospital; Female; Gastroenteritis; | 2016 |
Emergency department management of gastro-enteritis in Australia and New Zealand.
Topics: Acute Disease; Antiemetics; Australia; Data Collection; Dehydration; Diarrhea; Emergency Medicine; E | 2008 |
Acute Akinesia, an unusual complication in Parkinson's Disease: a case report.
Topics: Acute Disease; Aged; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Creatine Kinase; Dis | 2008 |
Prevention of acute hematoma after face-lifts.
Topics: Acetaminophen; Acute Disease; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Antiemetics; | 2010 |
[Ondansetron use in paediatric emergencies].
Topics: Acute Disease; Antiemetics; Child; Dose-Response Relationship, Drug; Gastroenteritis; Humans; Intens | 2010 |
Antiemetics for acute gastroenteritis-related vomiting in children and adolescents.
Topics: Acute Disease; Adolescent; Antiemetics; Child; Dimenhydrinate; Gastroenteritis; Humans; Metocloprami | 2012 |
Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration.
Topics: Acute Disease; Animals; Behavior, Animal; Brain; Cocaine; Cocaine-Related Disorders; Disease Models, | 2002 |
Antiemetic use for gastroenteritis in children.
Topics: Acute Disease; Administration, Oral; Age Factors; Antiemetics; Child; Diarrhea; Emergency Treatment; | 2003 |
Ondansetron for acute gastroenteritis in children.
Topics: Acute Disease; Antiemetics; Child; Dehydration; Diarrhea; Fluid Therapy; Gastroenteritis; Humans; On | 2006 |
Re: selected summary of "antiemetics for acute gastroenteritis: a never ending story".
Topics: Acute Disease; Antiemetics; Fluid Therapy; Gastroenteritis; Humans; Ondansetron; Vomiting | 2007 |
Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chem | 2007 |
Ondansetron for intractable vertigo complicating acute brainstem disorders.
Topics: Acute Disease; Adult; Brain Diseases; Brain Stem; Humans; Middle Aged; Multiple Sclerosis; Ondansetr | 1995 |
Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia | 1993 |
[Acute postoperative pancreatitis, is it associated with the use of ondansetron?].
Topics: Acute Disease; Adolescent; Antiemetics; Humans; Nasal Bone; Ondansetron; Pancreatitis; Postoperative | 1997 |
Acute intracranial hypertension-induced inhibition of gastric emptying: evaluation in conscious rats.
Topics: Acute Disease; Analgesics, Non-Narcotic; Animals; Antihypertensive Agents; Antipsychotic Agents; Bre | 1999 |
Acute myocardial ischemia after administration of ondansetron hydrochloride.
Topics: Acute Disease; Antiemetics; Electrocardiography; Female; Humans; Injections, Intravenous; Middle Age | 2000 |
Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy.
Topics: Acute Disease; Age Factors; Antiemetics; Antineoplastic Agents; Body Weights and Measures; Chlorprom | 2000 |
Prevention of acute and delayed cisplatin-induced nausea and vomiting with intravenous ondansetron plus intravenous dexamethasone.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combinati | 2000 |
Who should receive a 5-HT3 antagonist?
Topics: Acute Disease; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin | 1992 |